Glumetinib is an oral targeted therapy agent indicated primarily for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. Prior to administration, confirmation of genetic testing results is required. The medication must be taken strictly as prescribed by a physician, with close attention to dosage adjustment, adverse reaction monitoring, and drug-drug interactions. Detailed precautions are as follows:
I. Indications and Administration Prerequisites
Patient Population
Applicable to patients with locally advanced or metastatic NSCLC confirmed to have MET exon 14 skipping mutations via genetic testing.
Contraindications
Patients with hypersensitivity to any component of the drug.
Patients with uncontrolled severe hepatic or renal insufficiency.
Pregnant women and lactating women.
II. Dosage and Administration
Usual Dosage
The recommended dose is generally a fixed amount once daily (specific dosage to be followed as prescribed by the physician), which can be taken either on an empty stomach or with meals.
Dosage Adjustment Principles
In case of severe adverse reactions (e.g., liver injury, interstitial lung disease), treatment should be suspended or dosage reduced. Subsequent treatment plans shall be determined by the physician based on comprehensive assessment.
Important Notes
The tablets must be swallowed whole; do not chew or crush them.
Avoid missing doses. If a dose is missed by more than 12 hours, skip the missed dose and resume the regular daily dose the next day.
III. Adverse Reactions and Management
Common Reactions
Edema, fatigue, nausea, decreased appetite, diarrhea, etc. These symptoms are usually tolerable, but medical attention should be sought if they persist or worsen.
Severe Reactions
Interstitial Lung Disease/Pneumonitis
Immediately discontinue the medication and consult a doctor if symptoms such as dyspnea or worsening cough occur.
Hepatic Toxicity
Monitor liver function regularly. Treatment should be suspended if transaminase levels increase more than 3 times the upper limit of normal.
Hypersensitivity Reactions
Rash, pruritus, facial swelling, etc., require prompt medical intervention.
IV. Drug-Drug Interactions
Concomitant Use to Avoid
Potent CYP3A4 inducers (e.g., rifampicin) may reduce the efficacy of glumetinib.
Potent CYP3A4 inhibitors (e.g., ketoconazole) may increase the risk of glumetinib-related toxicity.
Drugs to Be Used with Caution
Anticoagulants and non-steroidal anti-inflammatory drugs may increase bleeding risk; close monitoring is required during concurrent use.
V. Special Populations and Storage
Pregnant/Lactating Women
Glumetinib has teratogenic potential. Effective contraceptive measures must be adopted during treatment and after drug discontinuation.
Patients with Hepatic/Renal Impairment
Dosage adjustment is necessary for patients with moderate to severe hepatic or renal insufficiency, and relevant indicators should be monitored regularly.
Storage Conditions
Store in a cool, dry place away from light, at a temperature below 25℃. Keep out of reach of children.
Important Reminder
Glumetinib is a prescription-only medication and must be used under the supervision of an oncologist. During treatment, imaging examinations and blood tests should be conducted every 2-3 months to dynamically evaluate treatment efficacy and safety. If new symptoms emerge or existing symptoms deteriorate, contact the attending physician immediately to adjust the treatment plan.
